Objective:To investigate the effects of growth hormone combined with triptoreline acetate on growth and sex hormone in girls with central precocious puberty.Methods:Sixty-two girls with central precocious puberty who received treatment in Xin'an International Hospital from January 2017 to December 2019 were included in this study. They were randomly assigned to receive treatment with either triptorelin acetate (control group, n = 31) or triptorelin acetate plus growth hormone (observation group, n = 31) for 12 successive months. Before and after treatment, bone age difference/chronological age difference (△BA/△CA), body height, body weight, uterine and ovarian volume and sex hormone level were compared between the control and observation groups. Results:△BA/△CA in the observation group was significantly lower than that in the control group [(0.64 ± 0.17) vs. (0.95 ± 0.13), t = 8.065, P < 0.05). Body height and weight in the observation group were (127.32 ± 1.08) cm and (33.42 ± 2.37) kg, respectively, which were significantly higher than those in the control group [(126.34 ± 0.87) cm and (31.01 ± 2.15) kg, t = 3.934 and 4.193, both P < 0.05]. Uterine and ovarian volume in the observation group were (1.68 ± 0.29) cm 3 and (1.26 ± 0.18) cm 3, respectively, which were significantly lower than those in the control group [(2.41 ± 0.46) cm 3 and (1.83 ± 0.26) cm 3, t = 7.474 and 10.036, both P < 0.05). After treatment, there were no significant differences in serum estradiol and luteinizing hormone levels between the two groups (both P > 0.05). Conclusion:Growth hormone combined with triptoreline acetate has a good effect on central precocious puberty in girls because it can improve the growth and development of girls and reduce serum levels of estradiol and luteinizing hormone.

Objective:To investigate the effect of montelukast sodium combined with glucocorticoid on acute attack of children with bronchial asthma and its influence on cytokines and immune function.Methods:A total of 122 children with acute asthma attack admitted to Xin'an International Hospital from September 2018 to September 2019 were divided into observation group(61 cases) and control group(61 cases) according to the random digial table mrethod.The control group was treated with glucocorticoid, and the observation group was treated with montelukast sodium on the basis of the control group.The course of treatment in both two groups was 7 days.The therapeutic effect, lung function, cytokines and immune function of the two groups were compared before and after treatment.Results:The total effective rate of the observation group(91.80%) was higher than 73.77% of the control group (χ 2=6.960, P<0.05). The peak expiratory flow rate(PEFR)[(2.93±0.21)L/s], forced expiratory volume in the first second(FEV 1%)[(82.54±5.37)%] and forced expiratory volume/forced vital capacity in the first second(FEV 1/FVC)[(90.32±4.36)%] in the observation group were higher than those in the control group[(2.48±0.16)L/s, (75.42±3.28)% and (83.98±3.42)%] ( t=13.313, 8.837, 8.936, all P<0.05). The levels of VEGF[(129.83±17.64)ng/L], TGF-β1[(83.21±16.79)ng/L] and IL-6[(24.32±4.19)ng/L] in the observation group were lower than those in the control group [(210.37±25.43)ng/L, (176.48±23.12)ng/L and (48.39±5.47)ng/L] ( t=20.325, 25.494, 27.284, all P<0.05). The CD 3+ [(75.72±3.46)%], CD 4+ [(42.56±3.18)%] and CD 4+ /CD 8+ (1.97±0.19) in the observation group were higher than those in the control group [(66.81±4.80)%, (37.87±2.63)% and (1.62±0.16)] ( t=11.761, 8.877, 11.005, all P<0.05). Conclusion:Montelukast sodium combined with glucocorticoid has obvious therapeutic effect on children with acute attack of asthma.It can reduce inflammatory reaction and enhance immune function, which is worthy of clinical reference.